United Therapeutics' drug fails PhII/III cancer trial, marking their second straight stumble in post-Remodulin PAH
Make that 0-for-their-last-2 for United Therapeutics.
Nearly a year after a drug candidate-killing PAH trial failure, United announced its Phase II/III trial combining their Unituxin antibody with a standard treatment, irinotecan, failed to help small cell lung cancer patients live longer.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.